Cargando…

CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen

Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors w...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestris, Nicola, Simone, Giovanni, Partipilo, Giulia, Scarpi, Emanuela, Lorusso, Vito, Brunetti, Anna Elisabetta, Maiello, Evaristo, Paradiso, Angelo, Mangia, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200864/
https://www.ncbi.nlm.nih.gov/pubmed/25198900
http://dx.doi.org/10.3390/ijms150915767
_version_ 1782340119505666048
author Silvestris, Nicola
Simone, Giovanni
Partipilo, Giulia
Scarpi, Emanuela
Lorusso, Vito
Brunetti, Anna Elisabetta
Maiello, Evaristo
Paradiso, Angelo
Mangia, Anita
author_facet Silvestris, Nicola
Simone, Giovanni
Partipilo, Giulia
Scarpi, Emanuela
Lorusso, Vito
Brunetti, Anna Elisabetta
Maiello, Evaristo
Paradiso, Angelo
Mangia, Anita
author_sort Silvestris, Nicola
collection PubMed
description Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors with different thymidylate synthase (TS) or topoisomerase-I (Topo-I) expression. Using immunohistochemistry (IHC), we evaluated the biological role of CES2 and the expression of breast cancer resistance protein (BCRP/ABCG2) in 58 consecutive mCRC patients, who had undergone a first-line CPT-11/5-FU/leucovirin (FOLFIRI) regimen. The expression of these proteins was also examined in a group of synchronous lymph nodes and liver metastases. Furthermore, all samples were revaluated for TS and Topo-I expression. High expression of CES2, ABCG2, TS and Topo-I was observed in 55%, 56%, 38% and 49% of patients, respectively. There was a significant association between high TS and high ABCG2 expression (p = 0.049). Univariate analysis showed that only TS expression significantly impacted on time to progression (p = 0.005). Moreover, Cox’ multivariate analysis revealed that TS expression was significantly associated with overall survival (p = 0.01). No significant correlation was found between investigated markers expression and clinical response. Topo-I expression resulted in being significantly higher in liver metastases with respect to the corresponding primary tumors (p < 0.0001), emphasizing the role of Topo-I expression in metastatic cancer biology. In primary tumor tissues, CES2 expression tended to be higher than that observed in liver metastasis tissues (p = 0.05). These preliminary data may suggest CES2 over-expression as a potential marker of malignant phenotype. In light of these findings, we suggest that Topo-I expression together with TS expression could be associated with metastatic progression of CRC. Further studies are warranted with the aim of evaluating the potential predictive and prognostic role of CES2 and ABCG2 in larger series of patients.
format Online
Article
Text
id pubmed-4200864
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42008642014-10-17 CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen Silvestris, Nicola Simone, Giovanni Partipilo, Giulia Scarpi, Emanuela Lorusso, Vito Brunetti, Anna Elisabetta Maiello, Evaristo Paradiso, Angelo Mangia, Anita Int J Mol Sci Article Enzymatic activation of irinotecan (CPT-11) is due to carboxylesterase (CES), and its pharmacological behavior is influenced by drug resistance-related proteins. We previously reported that the clinical response and prognosis of metastatic colorectal cancer (mCRC) patients did not differ in tumors with different thymidylate synthase (TS) or topoisomerase-I (Topo-I) expression. Using immunohistochemistry (IHC), we evaluated the biological role of CES2 and the expression of breast cancer resistance protein (BCRP/ABCG2) in 58 consecutive mCRC patients, who had undergone a first-line CPT-11/5-FU/leucovirin (FOLFIRI) regimen. The expression of these proteins was also examined in a group of synchronous lymph nodes and liver metastases. Furthermore, all samples were revaluated for TS and Topo-I expression. High expression of CES2, ABCG2, TS and Topo-I was observed in 55%, 56%, 38% and 49% of patients, respectively. There was a significant association between high TS and high ABCG2 expression (p = 0.049). Univariate analysis showed that only TS expression significantly impacted on time to progression (p = 0.005). Moreover, Cox’ multivariate analysis revealed that TS expression was significantly associated with overall survival (p = 0.01). No significant correlation was found between investigated markers expression and clinical response. Topo-I expression resulted in being significantly higher in liver metastases with respect to the corresponding primary tumors (p < 0.0001), emphasizing the role of Topo-I expression in metastatic cancer biology. In primary tumor tissues, CES2 expression tended to be higher than that observed in liver metastasis tissues (p = 0.05). These preliminary data may suggest CES2 over-expression as a potential marker of malignant phenotype. In light of these findings, we suggest that Topo-I expression together with TS expression could be associated with metastatic progression of CRC. Further studies are warranted with the aim of evaluating the potential predictive and prognostic role of CES2 and ABCG2 in larger series of patients. MDPI 2014-09-05 /pmc/articles/PMC4200864/ /pubmed/25198900 http://dx.doi.org/10.3390/ijms150915767 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Silvestris, Nicola
Simone, Giovanni
Partipilo, Giulia
Scarpi, Emanuela
Lorusso, Vito
Brunetti, Anna Elisabetta
Maiello, Evaristo
Paradiso, Angelo
Mangia, Anita
CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title_full CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title_fullStr CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title_full_unstemmed CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title_short CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
title_sort ces2, abcg2, ts and topo-i primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line folfiri regimen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200864/
https://www.ncbi.nlm.nih.gov/pubmed/25198900
http://dx.doi.org/10.3390/ijms150915767
work_keys_str_mv AT silvestrisnicola ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT simonegiovanni ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT partipilogiulia ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT scarpiemanuela ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT lorussovito ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT brunettiannaelisabetta ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT maielloevaristo ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT paradisoangelo ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen
AT mangiaanita ces2abcg2tsandtopoiprimaryandsynchronousmetastasisexpressionandclinicaloutcomeinmetastaticcolorectalcancerpatientstreatedwithfirstlinefolfiriregimen